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Hydrophilic lung surfactant proteins have emerged as key immunomodulators aimed at 
recognition and clearance of pulmonary pathogens. Surfactant protein A (SP-A) is a surfactant-
associated innate immune pattern recognition molecule, which is known to interact with a 
variety of pathogens, and display anti-microbial effects. SP-A, being carbohydrate pattern 
recognition molecule, has been suggested to have a wide range of innate immune functions 
against pathogens. In addition, SP-A can work against respiratory pathogens, including 
influenza A virus (IAV). Some pandemic pH1N1 strains resist neutralization by SP-A due to 
differences in the N-glycosylation of viral hemagglutinin (HA). Here, we provide evidence, for 
the first time, that a recombinant form of human SP-A (rfhSP-A) composed of -helical neck 
and carbohydrate recognition domains can actually promote the IAV replication, as observed 
by an upregulation of M1 expression in lung epithelial cell line, A549, when challenged with 
pH1N1 and H3N2 IAV subtypes. rfhSP-A (10 μg/ml) bound neuraminidase (NA) (~60kDa), 
matrix protein 1 (M1) (~25kDa) and M2 (~17kDa) in a calcium dependent manner, as revealed 
by far western blotting, and direct binding ELISA. However, human full length native SP-A 
downregulated mRNA expression levels of M1 in A549 cells challenged with IAV subtypes. 
Furthermore, qPCR analysis showed that transcriptional levels of TNF-α, IL-12, IL-6, IFN- 
and RANTES were enhanced following rfhSP-A treatment by both IAV subtypes at 6 h post-
IAV infection of A549 lung epithelial cells. In the case of full length SP-A treatment, mRNA 
expression levels of TNF-α, and IL-6 were downregulated during the mid-to-late stage of IAV 
infection of A549 cells.  Multiplex cytokine/chemokine array revealed enhanced levels of both 
IL-6 and TNF-α due to rfhSP-A treatment in the case of both IAV subtypes tested, while no 
significant effect was seen in the case of IL-12. Enhancement of IAV infection of pH1N1 and 
H3N2 subtypes by truncated rfhSP-A, concomitant with infection inhibition by full-length SP-
A, appears to suggest that a complete SP-A molecule is required for protection against IAV. 
This is in contrast to a recombinant form of trimeric lectin domains of human SP-D (rfhSP-D) 








The initial response to an infection in a host is the activation of its innate immune system. 
Understanding how innate immune mechanisms restrict the spread of respiratory infections is 
crucial to designing therapeutic strategies. Influenza virus has been a major infectious 
respiratory pathogen, and remains a serious global health concern, resulting in up to half a 
million respiratory deaths annually (WHO 2018). There are four distinct types of Influenza 
virus, which have been reported to cause infections in humans; influenza virus A (IAV) 
represents the most common cause of significant health threat. IAV is responsible for 
approximately 70% of all influenza related deaths, and has caused highly pathogenic 
pandemics (WH0 2009). IAV is further classified into different subtypes, depending on the 
combination of their surface glycoproteins, hemagglutinin (HA) and the neuraminidase (NA) 
(Bouvier et al., 2008). IAV has been reported to exert a greater selective pressure on the host, 
with a complex pathogenesis characterised by rapid viral replication, and viral distribution 
within the lungs, while evoking cellular and humoral immunity (Fukuyama et al., 2011).  
Although IAV has evolved numerous molecular strategies to avoid and escape the host’s 
immune responses, and to promote continuous survival within the host, a range of immune 
responses could potentially target any stage of IAV. 
The pulmonary surfactant system is composed of abundant proteins and lipids that lower the 
surface tension of the alveoli, and suggested to play important roles in innate immunity. Its 
hydrophilic proteins, also called collectins, are soluble collagenous lectins that serve multiple 
antimicrobial functions against influenza viruses by binding to oligosaccharide structures via 
conserved carbohydrate recognition domains on the surface of viral particles (van de Wetering 
et al., 2004). The interaction between IAV and collectins (found within the mammalian serum 
and pulmonary fluids) leads to anti-viral activity in vitro (Reading et al., 1997). Bovine 
conglutinin and mannose binding protein (MBP) cause inhibition of IAV hemagglutination and 
neutralisation (Hartley et al., 1992). Other collectins, including surfactant protein A (SP-A) 
and SP-D, expressed in the lungs, mucosal and epithelial surfaces in the body, are involved in 
a number of immune functions involving neutralization, agglutination, opsonisation and 
clearance of pathogens.  
SP-A is a collagenous calcium-dependent defense lectins, composed of N terminal domain rich 
in cysteine, collagen domain, an α-helical coiled-coil neck and C-terminal with carbohydrate 
recognition domain (CRD) (Kishore et al., 2006; Nayak  et al., 2012). The overall structure of 
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SP-A is made up six of these subunits, which look like a bouquet (Kishore et al., 2006). The 
trimeric CRD region recognises pathogens by engaging terminal monosaccharide residues or 
charged patterns on microorganisms, serving as soluble pattern recognition receptors (PRRs). 
Thus, collagen like region is crucial for the interaction with immune cell-mediated receptors 
such as calreticulin-CD91 complex to bring about removal of pathogens (Kishore et al., 2006; 
Gardai et al., 2003).  
Direct interaction between SP-A and various viruses results in viral neutralisation and 
induction of phagocytosis in vitro. SP-A can interact with glycoprotein 120 of HIV-1 and 
suppress infection of CD4+ T cells, and enhance HIV-1 transfer via dendritic cells, serving as 
a dual modulator of HIV-1 infection (Gaiha et al., 2008). SP-A has also been shown to interact 
with herpes simplex virus type 1 (HSV-1), and mediate phagocytosis of HSV-1 by alveolar 
macrophages (van Iwaarden et al., 1991). SP-A can bind to the F2 subunit of respiratory 
syncytial virus (RSV) and neutralise its infectivity (Ghildyal et al., 1999). In the case of IAV, 
SP-A can bind HA and NA, and inhibit haemagglutination at initial stages. However, pH1N1 
pandemic strains are not neutralised by SP-A due to variations in the N-linked glycosylation 
of HA (Job et al., 2010). We have recently shown a recombinant form of human surfactant 
protein D, containing homotrimeric neck and CRD region (rfhSP-D), binds HA and reduces 
M1 expression in A549 cells challenged with pH1N1 and H3N2 strains ( Al-Ahdal et al., 2018). 
In addition, mRNA expression levels of TNF-α, IFN-, IFN-, IL-6 and RANTES production 
were down-regulated following rfhSP-D treatment. Furthermore, rfhSP-D also reduced MDCK 
cell transduction by H1+N1 pseudotyped lentiviral particles, suggesting a possible therapeutic 
modality against IAV infection. In this regards, this study was aimed as investigating the 
possible role of a well-characterised recombinant truncated form of human SP-A (rfhSP-A) 
made up of trimeric CRDs, using pH1N1 and H3N2 IAV subtypes.  
Method and Materials  
Virus and antibodies 
A/England/2009 (pH1N1) and the A/HK/99 (H3N2) influenza A subtypes were used for most 
experiments. Vesicular Stomatitis Virus (VSV-G) was used as a control for ELISA. 
Monoclonal Anti-Influenza Virus NA, A/California/04/2009 (pH1N1) pdm09, Clone 5C12 
(produced in vitro), NR-42019 and A/Hong Kong/1/1968 (H3N2) (antiserum, Goat), NR-3118 
and anti-M1 monoclonal antibody were obtained from BEI Resources, NIAID, NIH, USA. 




Most reagents were purchased from Sigma unless mentioned otherwise. A549 and MDCK cell 
lines were cultured in complete DMEM containing FBS (10%), L-glutamine (2 mM), penicillin 
(100 U/ml), streptomycin (100 μg/ml) and sodium pyruvate (1 mM). Cells were cultured at 
37°C in a CO2 incubator until they were 80% cell confluent. Cells were trypsinised (0.5%; 10 
min), spun at 1000 rpm for 7’, and suspended in complete DMEM. Viable cells were counted 
via Trypan Blue (0.4%). 
Virus purification and infection titre determination 
Purification and production of pH1N1 and H3N2 subtypes were carried out as described earlier 
(Al-Ahdal et al., 2018). MDCK cells were infected with pH1N1 (2 × 104) or H3N2 (3.3 ×104) 
by incubation at 37°C for 1 h. Post infection, the viral particles were pelleted via 3,000×g 
centrifugation at 4°C for 10’. Supernatants containing virus particles were then subjected to 
ultracentrifugation (25,000×g, 4°C, 1 h 30’), followed by re-suspending virus in 100μl of PBS. 
15μl of virus stock was assessed via reduced SDS-PAGE and ELISA. Tissue culture infectious 
dose (TCID50) assay was performed to determine the infectious titre of the purified pH1N1 and 
H3N2 viral stocks, and to access its cytopathic effects (CPE) using MDCK cells, as reported 
recently (Al-Ahdal et al., 2018). CPE effects of infected and non-infected cells were 
microscopically examined at each viral dilution. 
Production of rfhSP-A 
DNA sequences coding for trimeric neck and CRD region were cloned under T7 promoter and 
expressed in Escherichia coli BL21 (λDE3) pLysS using construct pUK-A1 (Karbani et al., 
2014). E. coli cells were grown in LB medium, containing 100 μg/ml ampicillin and 34 μg/ml 
of chloramphenicol at 37°C until an OD600 reached of 0.6. Following induction with 0.5mM 
isopropyl β-D-thiogalactoside (IPTG), the bacterial culture was left to grow further for another 
3 h on a shaker at 37°C. The bacterial cell pellet was then centrifuged (4500 rpm, 4°C, 10’) 
and re-suspended in lysis buffer (0.05 M Tris-HCL pH 7.5, 0.2M NaCl, 0.005 M EDTA, 0.1% 
Triton X-100, 0.1 mM phenylmethane sulfonyl fluoride (PMSF), 50 μg lysozyme) for 1 hour 
at 4°C. The lysate was sonicated using a Soniprep 150 (MSE, London, UK) at 60 Hz for 30 
seconds with an interval of 2 min (12 cycles), followed by centrifugation at 12000 rpm for 15 
minutes. The inclusion bodies were denatured fully in 50 ml of 0.5 M Tris-HCl, 0.1M NaCl, 
pH7.5 and 8 M urea for 1 h at 4°C. The soluble fraction was dialysed against the same buffer 
containing 4 M, 2 M, 1 M and no urea for 2 h at each urea concentration. The refolded material 
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was then extensively dialysed against affinity buffer that contained 10 mM CaCl2 instead of 5 
mM EDTA for 2 h. The supernatant was loaded on a 5ml of mannose-sepharose column, and 
bound rfhSP-A was eluted with buffer with 10mM EDTA. Purified rfhSP-A was run on SDS-
PAGE to assess its purity. LPS was removed using Endotoxin Removal  Resin. LPS level was 
determined using QCL-1000 Limulus amebocyte lysate system (Lonza) and found to be ~5 
pg/μg of rfhSP-A. 
Extraction of full length native SP-A from human bronchoalveolar lavage fluid  
Human full-length native SP-A (FLSP-A) was purified as published earlier by Strong et al. 
(Strong et al., 1998). Bronchoalveolar lavage fluid (BAL) collected from pulmonary alveolar 
proteinosis patients was made up with buffer I containing 20 mM Tris-HCl and 10mM EDTA, 
pH 7.4, followed by centrifugation at 10,000 × g. The centrifuged cell pellet was extracted 
using buffer I with 6 M urea. The solubilised FLSP-A was centrifuged again at 10,000 × g and 
the soluble fraction was dialysed against 4, 2, and 1 M urea in buffer II ( 20 mM Tris-HCl, 100 
mM NaCl, and 5 mM EDTA, pH 7.4). The supernatant was again dialysed against buffer II 
containing 15mM CaCl2, and loaded onto maltose agarose column, followed by elution with 
10 mM EDTA.    
SDS-PAGE Electrophoresis 
SDS-PAGE 12% (w/v) was performed to analyse and detect the purity of purified rfhSP-A and 
FLSP-A. Purified proteins were diluted in 1:1 (v/v) ratio in 2× Laemmli sample buffer (10ml) 
(Bio-Rad, Hertfordshire, catalogue no.161-0737) containing1M Tris-HCL (PH 6.8, 1ml), 10% 
SDS (4ml), 100% Glycerol (2ml), 1% Bromophonol blue, β-mercaptoethanol (2.5ml) and 
distilled water (d.H2O) (Bio-Rad, Hertfordshire). The protein was then denatured for 10 
minutes at 95°C before loading onto 12% (w/v) SDS-PAGE. Standard pre-stained protein 
marker (Fisher Scientific) was also loaded to assess the size of the purified rfhSP-A. The SDS-
PAGE gel was stained overnight using staining solution (1g of Brilliant Blue, 50% (v/v) 
methanol, 10% acetic acid and 40ml of D.H2O). The stained gel was then de-stained using the 
de-staining solution 40% (v/v) methanol, 10% (v/v) acetic acid until the protein bands were 
visible. 
Direct Binding ELISA 
The interaction between rfhSP-A and IAV subtypes was measured via direct ELISA. A varied 
concentrations of FLSP-A, rfhSP-A, rfhSP-D and VSV-G (as a negative control protein) (10, 
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5, 2.5, and 1.25 μg/well) were coated on microtitre wells of a Maxisorp 96 well plate (Sigma-
Aldrich) in carbonate bicarbonate buffer, pH 9.6 and incubated at 4°C overnight. After washing 
with PBS three times, the unoccupied sites on the wells were blocked with 2% w/v BSA for 2 
h at 37°C, and then followed by washing with PBST (PBS + 0.05% Tween 20). pH1N1/H3N2 
virus (20 μl of 1.36×106 pfu/ml) was diluted 10 times using PBS, and 10 μl of it incubated in 
the wells for 2 h at RT. After washing, monoclonal anti-H1 and polyclonal anti-H3 (both from 
BEI-Resources) in PBS (1:5000) were added to the appropriate wells and incubated at 37°C 
for 1 h, followed by 1 h incubation with rabbit anti-mouse and protein A conjugated to HRP 
(1:5000) (both from Fisher Scientific). TMB was used as a substrate and the plate was read at 
OD450. 
Far Western Blotting   
Purified pH1N1/H3N2 (1.36×106pfu/ml) was run on SDS-PAGE and then separated proteins 
were transferred to a PVDF membrane using transfer buffer (0.25 M Tris, 0.19 M glycine and 
20% methanol). After blocking the membrane with 5% w/v milk power in PBS at 4°C and 
washing, the membrane was probed with monoclonal anti-NA, M1 or M2 (1:1,000 dilutions) 
antibodies for 1h at RT. For far-western blotting, the membrane was incubated with 5μg/ml of 
rfhSP-A in 5mM CaCl2 buffer overnight at 4°C. Binding was probed with rabbit anti-human 
SP-A in PBS (1:1000) for 1h at RT.  Rabbit anti-mouse and Protein A conjugated to HRP 
(1:5000) (Fisher Scientific) were used as respective conjugates/secondary probes for 
polyclonal and monoclonal antibodies. The colour was developed using DAB as a substrate 
and H2O2. 
Cell-Binding assay 
A549 cells (10,000 cells per well) were seeded in complete DMEM and incubated at 37°C until 
80% confluence was reached. After washing with different concentration of purified rfhSP-A 
(1.25 to 10 μg/ml) were pre-treated with pH1N1/H3N2 virus (1.36 × 106 pfu/ml). 10μl of 
diluted virus stock was added to the appropriate wells, and incubated for 2 h at RT.  After fixing 
the wells with 4% v/v paraformaldehyde (Fisher Scientific) for 10’ at RT, blocking step was 
carried out using 2% w/v BSA as described above. Anti-H1 and H3 antibodies and secondary 






rfhSP-A and FLSP-A (10 μg/ml) was added to A549 cells (0.5 × 106) in DMEM + 5mM CaCl2 
with MOI 1 of H1N1/H3N2 virus and pelleted at different time points. Total RNA was 
extracted from the above-mentioned cells using GenElute Mammalian Total RNA Purification 
Kit (Sigma-Aldrich, UK). Total RNA was treated with DNase I (Sigma-Aldrich, UK) prior to 
assessing concentration and purity of total RNA  via reading at OD260 and 
OD260:OD280 (NanoDrop 2000/2000c; Thermo Fisher Scientific). 2 µg of RNA was converted 
into cDNA using cDNA Kit (Applied Biosystems). qRT-PCR was performed using the 
7900HT Fast Real-Time PCR System (Applied Biosciences). Each reaction was carried out in 
triplicates and included 5µl Power SYBR Green MasterMix, 75 nM of FP and RP, and 500 ng 
cDNA. The amplification cycle involved  50°C and 95°C for 2’ and 10’, followed by 40 cycles 
of amplification. Human 18S rRNA was used to normalise gene expression and as an 
endogenous control.  
Multiplex cytokine array analysis  
In order to measure the secreted cytokines and chemokines following rfhSP-A treatment, IAV 
treated A549 cells were incubated in the presence or absence of rfhSP-A (10 µg/ml) for 24 h. 
Subsequently, supernatants were collected for measuring IL-6, TNF-α, IL-8, IL12 (p40) and 
MCP-1. The expression levels of various analytes were measured using EMD Millipore 
multiplex kit. As per manufacture’s instruction, 25µl assay buffer was added to microtiter 
wells, plus 25µl standard, control or supernatant of A549 cells. Magnetic beads (25 µl) linked-
analytes were added to each well and incubated at 4˚C for 18 h. After assay buffer washing, 
detection antibodies (25µl) were incubated with beads at RT for 1 h. 25µl of Streptavidin-
Phycoerythrin was then added to each well and incubated for 30 mins at RT. After another 
round of washing, 150 µl of sheath fluid was added to each well and the plate was read using 
the Luminex Magpix instrument. 
Statistical Analysis 
GraphPad Prism 6.0 software was used to generate all the graphs. Two-way ANOVA test was 
used to perform the statistical analysis, and the significance values were considered between 
rfhSP-A treated and untreated conditions based on *p<0.1, **p< 0.05, ***p< 0.01, and ****p< 





Interaction of affinity purified rfhSP-A with pH1N1/H3N3 viral particles  
The affinity purified and LPS-free rfhSP-A was evident as a single band at ~18 kDa on 15% 
SDS-PAGE (v/v) under reducing condition (Figure 1). The direct binding interaction of FLSP-
A, rfhSP-A, and rfhSP-D with pH1N1/H3N2 viral particles were determined using ELISA. As 
shown in figure 2, FLSP-A, rfhSP-A and rfhSP-D bound IAV subtypes in a dose and calcium-
dependent manner. No significant binding was observed with VSV-G pseudotyped lentivirus 
(negative control RNA virus). Cell binding assay was also performed to assess the interaction 
of rfhSP-A with A549 lung epithelial cells challenged with pH1N1 and H3N2 (Figure 3). 
Maximum cell binding was seen with 10 µg/ml in both IAV subtypes, while a clear dose 
dependent binding was seen with H3N2, compared to pH1N1.   
rfhSP-A interaction with NA, M1, and M2 proteins of pH1N1 and H3N2  
Binding of rfhSP-A to NA (~60 kDa), M1 (~25kDa) and M2 (~17 kDa) of purified pH1N1 and 
H3N2 was established using far western blotting (Figure 4A). The ability of rfhSP-A to bind 
immobilised purified recombinant NA was assessed using ELISA. As shown in figure 4C, 
rfhSP-A interacted with NA dose- and calcium-dependently; VSV-G-pseudotyped particles did 
not show significant binding.  Polymerization of M1 is suggested to provide a crucial 
mechanism for the elongation of filamentous IAV virions. In addition, rfhSP-A was also found 
to bind matrix protein 2 (M2) migrating at ~17kDa, as evident from western blotting (Figure 
4A). Binding of rfhSP-A to M2 protein may suggest enhancement of viral replication by 
stabilising the viral budding site, enabling M2 polymerization leading to formation of 
filamentous viral particles. 
rfhSP-A promotes, while FLSP-A inhibits, infection of A549 cells by IAV  
Infection assay was performed to determine the ability of IAV to infect A549 cells in the 
presence or absence of FLSP-A and rfhSP-A (10 μg/ml). rfhSP-A treatment up-regulated M1 
expression in infected A549 cells when compared to untreated cells challenged only with virus 
(Figure 5). In the case of both IAV subtypes, rfhSP-A treatment upregulated M1 expression at 
2 and 6 h. The up-regulation of M1 expression was more pronounced for H3N2 than pH1N1, 
where 7log10 fold up-regulation was noted at 6 h (Figure 5A). M1 is known to bind cytoplasmic 
ends of HA and NA of IAV, allowing M1 association with lipid raft membrane, and inducing 
change in its conformation and polymerization at the site of virus budding (Gómez-Puertas et 
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al., 2000). However, FLSP-A caused downregulation of M1 expression at 2h and 6h in the case 
of both IAV subtypes. The suppression of M1 following FLSP-A treatment was more evident 
in the case of pH1N1 when compared to H3N2, where -5 log10 fold reduction was seen at 6h 
(Figure 5B). This data is consistent with another study using rfhSP-D, where -8 log10 fold 
downregulation of M1 expression was seen with pH1N1 at 2h (Al-Ahdal et al., 2018). 
qRT-PCR analysis of modulation of immune responses by rfhSP-A on A549 challenged 
with IAV subtypes  
The mRNA levels of pro-inflammatory cytokines and chemokines were determined via qPCR. 
The relative mRNA levels of TNF-α, IL-12, IFN-, and RANTES were upregulated by both 
IAV strains, following rfhSP-A treatment at 6h time point. However, IL-6 was 2log10 fold 
upregulated by pH1N1 at 6h by rfhSP-A treatment (Figure 6A), but no significance change was 
found with H3N2 strain at 6h. Furthermore, enhancement of IFN-α was also evident with 
rfhSP-A treatment at both 2h, which gradually declined by 2.log10 fold at 6h (Figure 7A). 
Upregulation of type I interferon may suggest that rfhSP-A can enhance viral replication, and 
thus, increase the levels of interferon type I response to alert other immune cells to mobilise 
mechanisms towards viral clearance. In the case of FLSP-A treatment, pro-inflammatory 
cytokines such as TNF-α and IL-6 were downregulated at 6h treatment in both pH1N1 and 
H3N2 ( Figure 6C & D). Enhanced level of IL-6 has been reported in patients infected with 
pH1N1 (Paquette et al., 2012). IL-12 (-2 log10 fold) and RANTES (-6.5 log10 fold) were 
downregulated by FLSP-A treatment in pH1N1 subtype (Figure 6C), while upregulation was 
seen with H3N2 (Figure 6D), suggesting the possible enhancement of Th1 immune response. 
In the case of type I interferons, FLSP-A has induced upregulation of INF-α at 6h in both IAV 
strains. 
Multiplex analysis of cytokine/chemokine array following rfhSP-A treatment  
Secretion of cytokines and chemokines, 24h post rfhSP-A treatment, was assessed using a 
multiplex cytokine/chemokine array. rfhSP-A  triggered  enhancement of  TNF-α, IL-6 and IL-
8 in both IAV subtypes (Figure 8). However, no significance effect was seen with MCP-1 for 
both IAV subtypes.  Increased IL-6 level has been linked with the severity of IAV infection 
based on a study involving pH1N1-infected mice (Paquette et al., 2012). Expression of TNF-α 
in lung epithelial cells is suggested to be the key targets of IAV, and appeared to be important 
to control IAV in the host respiratory tract. TNF-α is involved in recruiting monocytes, T and 
B lymphocytes to the site of infection, suggesting that its role in clearing the viral particles in 
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the respiratory tract prior to the induction of secondary immune response. Therefore, up-
regulation of TNF-α and IL-6 by rfhSP-A can serve as a potential biomarker during IAV 
infection, similar to other diseases (Damas et al., 1992; Theoharides et al., 2002). 
Discussion 
Influenza A virus (IAV) is a contagious respiratory virus, causing substantial morbidity and 
mortality. Anders et al first reported collectins as beta inhibitors derived from bovine and 
mouse. The calcium dependent mannose binding lectin (MBL) was shown to bind glycans 
found on the globular region of HA, thus, inhibiting HA from binding to sialic acid-decorated 
ated cell-surface receptors (Anders et al., 1990). Collectins can orchestrate a number of anti-
IAV mechanisms such as inhibition of HA and NA (Hartshorn et al., 1994; 2008; Al-Ahdal et 
al., 2018), virus neutralisation, virus aggregation, IAV uptake by neutrophils, and viral 
opsonisation. SP-A is a calcium-dependent hydrophilic C-type collectin, involved in 
pulmonary surfactant homeostasis (Weaver et al., 1991), and reported to be a potent innate 
immune molecule in the lungs. SP-A can bind various self and non-self-ligands in a calcium- 
dependent manner, mostly via CRD region on the target surface. Thus, recruitment and 
activation of immune cells occurs via collagen domain for the clearance of microorganisms 
(Kishore et al., 2006). SP-A can bind a diverse group of pathogens, acting as opsonins leading 
to direct and indirect biological consequences (Crouch et al., 2000, Lawson et al., 2000, Crouch 
et al., 2001). Specific interaction of SP-A with a number of respiratory viruses has been 
reported, which requires interaction between viral glycoproteins and complex oligosaccharides 
found on SP-A. Recently, we described a protective effect of rfhSP-D that was able to inhibit 
entry of IAV into A549 cells challenged with pH1N1 and H3N2 subtypes (Al-Ahdal et al., 
2018).  Therefore, this study was aimed at examining the direct interaction of a truncated 
recombinant fragment of human SP-A (rfhSP-A) with IAV, and subsequent immunological 
consequences.  
In this study, protein-protein interaction between rfhSP-A and IAV subtypes (pH1N1 and 
H3N2). Plasmid pUK-A1, containing cDNA sequences for neck and CRD region of human 
SP-A (Karbani et al., 2014) was transformed in Escherichia coli BL21 (λDE3) pLysS strain 
under T7 bacteriophage promoter. rfhSP-A, recovered from inclusion bodies via denaturation-
renaturation cycles, was affinity purified on a mannose-agarose column, which appeared as a 
~18kDa band on a 15% SDS-PAGE gel electrophoresis (Figure 1). rfhSP-A eluted as a trimer 
on a gel filtration column and was recognised by rabbit polyclonal and mouse monoclonal 
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antibodies raised against full length SP-A purified from lung lavage of an alveolar proteinosis 
patient (data not shown). Affinity purified rfhSP-A made free from endotoxin, was then 
examined for its respective interaction with IAV subtypes (pH1N1 and H3N2) via direct 
ELISA (Figure 2). The ability of FLSP-A, rfhSP-A and rfhSP-D to bind IAV subtypes is 
consistent with an earlier study using a recombinant form of truncated human SP-D (rfhSP-D) 
composed of trimeric neck and CRD region (Al-Ahdal et al., 2018). 
The 10 μg/ml of rfhSP-A bound best to both pH1N1 and H3N2 (Figure 2). The ability of rfhSP-
A to bind IAV bound A549 cells was measured via cell binding assay (Figure 3). To understand 
whether interaction between rfhSP-A and IAV subtypes led to specific interaction with IAV 
glycoproteins, far western blotting analysis was carried out (Figure 4A). rfhSP-A (10 μg/ml) 
bound to NA (~60 kDa), M1 (~25kDa)  and M2 (~17kDa) of purified pH1N1 and H3N2 in a 
calcium-dependent manner. Furthermore, in order to validate the binding interaction rfhSP-A 
and NA, an ELISA was carried out using purified recombinant NA protein. As evident in figure 
4B, rfhSP-A bound purified NA protein dose-dependently. Previous studies have also 
suggested that full length SP-A can bind to NA, and inhibit the release of viral particles from 
infected cells (Tecle et al., 2007). Thus, N-linked oligosaccharides found on NA are likely to 
be recognised by the CRD region of SP-A and SP-D (Tecle et al., 2007). 
The ability of rfhSP-A to modulate viral replication and enhance host response immune 
response by IAV challenged A549 cells following rhSP-A treatment was also examined. IAV- 
bound rfhSP-A was found to induce enhanced viral replication, based on the expression levels 
of M1 gene. M1 is an abundant matrix protein of IAV, which plays dual roles in virion 
assembly and infection (Rossman et al., 2011). Up-regulation of M1 expression was brought 
about by rfhSP-A treatment in IAV challenged A549 cells, compared to cells without rfhSP-A 
treatment but challenged with pH1N1 or H3N2 only (Figure 5). M1 upregulation, following 
rfhSP-A treatment was effective in H3N2 infected cells compared to pH1N1, where 7log10 fold 
upregulation was seen at 6 h (Figure 5). However, A549 cells, pre-treated with FLSP-A, caused 
downregulation of M1 expression when compared to cells only challenged with IAV subtypes 
(Figure 5B). M1 downregulation by FLSP-A was found to be more effective in pH1N1 subtype, 
when compared to H3N2, where -5 log10 fold downregulation was evident at 6h treatment 
(Figure 5B). M1 can bind cytoplasmic ends of HA and NA, polymerize and form the interior 
structure of emerging viral particles (Rossman et al., 2011). Additionally, as evident in far 
western blotting, rfhSP-A was also able to bind Matrix protein 2 (M2) of IAV at ~17 kDa 
(Figure 4). HA bound M1 also suggested to serve as docking site for the viral RNPs recruitment 
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and may mediate M2 recruitment to the site of viral budding (Rossman et al., 2011). M2 can 
stabilise the budding site, enabling polymerization of the matrix protein, leading to formation 
of viral particles. Furthermore, M2 has also been reported to change so as to facilitate release 
of the progeny viral particles. Binding of rfhSP-A to NA/M1/M2, and upregulation of M1 
expression could suggest the likely role of rfhSP-A as a facilitator of IAV replication of 
subtypes tested in this study.  
mRNA expression of pro-inflammatory cytokines and chemokines following rfhSP-A 
treatment were determined by qPCR. Our qPCR data showed an upregulation of TNF-α, IL-12 
and RANTES in the case of both IAV subtypes at 6h time point. However, an increased 
expression levels of IL-6 (2log10 fold) (Figure 6A) was seen only with pH1N1 at 6h, while 
H3N2 did not show any significant effect (Figure 6B). In contrast, downregulation of TNF-α 
(-4.5 log10 fold) and IL-6 (-5 log10 fold) was seen at 6h following FLSP-A treatment (Figure 6C 
& D). In the case of pH1N1, FLSP-A also caused downregulation of IL-12 and RANTES 
mRNA expression (Figure 6C), while increased expression levels was observed with H3N2 
IAV subtype (Figure 6D).  Enhanced levels of TNF-α and IL-6 have been reported during IAV 
infection, and it is also associated with severe lung pathology and worse outcome in IAV 
infected patients (La Gruta et al., 2007). However, these cytokines can also be protective during 
seasonal influenza infection. Studies also report increased level of IL-6 in the lungs and serum 
of patients infected with influenza virus, including the outbreak 2009 pH1N1 pandemic subtype 
(Kaiser et al., 2001, Hagau et al., 2010), which is being examined in this study. Therefore, 
increased levels of IL-6 following rfhSP-A treatment may be associated with facilitation of 
IAV infection, and acute lung injury.  
Increased serum levels of TNF-α has been reported in most influenza infected patients, 
particularly pH1N1 subtype (Hagau et al., 2010, Zúñiga et al., 2011, Bermejo-Martin et al., 
2010, Morales-García et al., 2012). In this study, when  pH1N1 and H3N2 were treated  with  
rfhSP-A,  TNF-α expression levels were enhanced at  6 h  (Figure  6), suggesting the ability of 
rhSP-A to increase viral infection, or virus-mediated respiratory diseases. Overexpression of 
TNF-α and IL-6 has been suggested as a hallmark of viral infection (Mogensen et al., 2001). 
Elevated levels of these cytokines haven been observed in patients with both acute (Kaiser et 
al., 2001) and severe (Heltzer et al., 2009) seasonal IAV infection. Up-regulation of cytokines 
production upon H1N1 infection has been reported as an important crucial player in the 
pathogenesis of IAV infection. Thus, invasion of H1N1 strain into the lungs has been reported 
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to trigger production of pro-inflammatory cytokine profile, resulting in the development of 
pneumonia.  
rfhSP-A treatment caused increased levels of IL-12 by both pH1N1 and H3N2 in a time 
dependent manner (Figure 6), suggesting the likely enhancement of viral replication and Th1 
immune response. RANTES  was  down-regulated in the presence of rfhSP-A at 2h, which 
recovered by 2.5log10 fold later  at 6 h time point in pH1N1 treated cells. However, for H3N2, 
only 1log10 fold upregulation was seen following rfhSP-A treatment in a time-dependent 
manner (Figure 6B). Lower expression levels of IFN-α  was observed  in  the  untreated  sample,  
which  was 3log10 fold  up-regulated  in  the  presence of rfhSP-A at 2h (Figure 7), suggesting 
that rfhSP-A can enhance the rate of viral replication, and thus, thereby enhance the levels of 
IFN produced by the innate immune cells in order to clear viral particles from infected host.   
In conclusion, a truncated recombinant form of human SP-A, rfhSP-A, can promote pH1N1 
and H3N2 subtypes of IAV instead of inhibition of infection. We have previously shown that 
its SP-D counterpart acts as an entry inhibitor (Al-Ahdal et al, 2018), suggesting that rfhSP-A 
may not have a therapeutic value. The effects of FLSP-A on IAV challenged A549 cells is 
similar to the effect seen by rfhSP-D, where downregulation of M1 and pro-inflammatory 
cytokines were seen with FLSP-A treatment. The observed restriction of M1 replication 
following FLSP-A treatment is likely to be due to the presence of collagen region, which could 
shift the way SP-A acts on IAV infectivity involving its putative receptor on the cell surface 
(Gardai et al, 2003). This study highlights a fundamental difference in the structure-function 
relationships between SP-A and SP-D. The literature is full of evidences where a recombinant 
truncated form of human SP-D (rfhSP-D) containing trimeric neck and CRD regions behave 
like full-length SP-D in vitro, in vivo and ex vivo, including offering a protective effect against 
IAV. In the case of SP-A and IAV interaction, it appears that only FLSP-A is capable of 
interfering with IAV entry into the target cells, highlighting the importance of the collagen 
domain and an intact SP-A molecule. It is also apparent that entry inhibition is coupled with an 
anti-inflammatory response, as evident from downregulation of TNF- and IL-6. However, 
both FLSP-A as well as rfhSP-A upregulate type I interferon (IFN-) response, raising the 
notion that FLSP-A creates an anti-inflammatory milieu during IAV infection. How rfhSP-A 
on its own enhances IAV infection remains an intriguing question. We are currently examining 
the mechanism of enhanced infectivity that may involve topological alterations in M1 and M2 
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Table 1: Target Genes, Forward and Reverse primers used for qPCR 
Target Forward Primer Reverse Primer 





IL-12 5′-AACTTGCAGCTGAAGCCATT-3′ 5′-GACCTGAACGCAGAATGTCA-3′ 
























Figure Legends  
Figure 1: SDS-PAGE (15% w/v) analysis of expression and purification of a recombinant 
fragment of Human Surfactant protein (rfhSP-A).  pUK-A1 construct containing neck and 
CRD region was expressed under T7 bacteriophage in Escherichia coli BL21 (λDE3) pLysS. 
Following IPTG induction, the expressed bacterial cells show rfhSP-A overexpression at ~18 
kDa. The inclusion bodies were refolded and affinity purified using a mannose-agarose 
column.  
Figure 2: Binding of rfhSP-A to (A) pH1N1 and (B) H3N2 via ELISA. Microtiter wells 
were coated with varied concentrations of FLSP-A, rfhSP-A and rfhSP-D (10, 5, 2.5, and 1.25 
µg/ml).  20 µl of concentrated pH1N1 or H3N2 virus (1.36 × 106 pfu/ml) was diluted in 200 µl 
of PBS + 5 mM CaCl2 and 10 µl of the diluted virus was added to all the wells, and probed 
with either monoclonal anti-influenza virus H1 or polyclonal anti-influenza virus H3 antibody. 
VSV-G pseudotyped lentivirus was used as a negative RNA virus control. The data were 
expressed as mean of three independent experiments done in triplicates ± SEM 
Figure 3: Cell-binding assay to show binding of (A) pH1N1 and (B) H3N2 pre-incubated 
with rfhSP-A to A549 cells. Microtiter wells were coated with A549 cells (1 × 105 cells/ml) 
and incubated overnight at 37°C. Different concentrations of rfhSP-A (10, 5, 2.5, and 1.25 
µg/ml) pre-incubated with pH1N1 and H3N2 virus were added to the corresponding wells, 
followed by incubation at room temperature for 2 h. After fixing the cells with 4% 
paraformaldehyde, monoclonal anti-influenza virus H1, or polyclonal anti-influenza virus H3 
antibodies were added to the corresponding wells. Maltose-binding protein (MBP) was used as 
a negative control protein. The data were expressed as mean of three independent experiments 
carried out in triplicates ± SEM 
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Figure 4: (A) Far western blot analysis to show rfhSP-A binding to purified pH1N1 and 
H3N2.  10 μl of concentrated virus (1.36 × 106 pfu/ml) was first run on the SDS-PAGE under 
reducing conditions, and then transferred onto a nitrocellulose membrane and incubated with 
10μg of rfhSP-A. The membrane was probed with anti-rabbit SP-A polyclonal antibody. rfhSP-
A bound to NA (~60 kDa), M1 (~25 kDa) and M2 (~17kDa) in the case of both pH1N1 and 
H3N2 subtypes. The identity of SP-A bound IAV proteins was validated using a separate blot 
that was directly probed with monoclonal anti-NA, M1 and M2 antibodies (B). (C) Direct 
ELISA to show the ability of rfhSP-A to bind purified recombinant neuraminidase (NA) 
of IAV. VSV-G was used as a negative control protein, where no significance binding was 
detected. The data were expressed as mean of three independent experiments carried out in 
triplicates ± SEM. Significance was determined using the unpaired one-way ANOVA test 
(***p< 0.0001)(n= 3  
Figure 5: rfhSP-A treatment promotes infection and replication (A), while suppression of 
M1 replication was seen with FLSP-A (B) of pH1N1 and (B) H3N2 in target human A549 
cells. M1 expression of both pH1N1 and H3N2 influenza A virus (IAV) (MOI 1) after infection 
of A549 cells at 2 and 6 h. A549 cells were incubated with  pH1N1 and H3N2 pre-incubated 
with or without purified rfhSP-A and FLSP-A (10 μg/ml). Cell pellets were harvested at 2 and 
6 h to analyze the M1 expression of IAV. Cells were lysed, and purified RNA extracted was 
converted into cDNA. Infection was measured via qRT-PCR using M1 primers; 18S was used 
as an endogenous control. Results shown are normalized to M1 levels at 2 h untreated. 
Significance was determined using the unpaired one-way ANOVA test (**p< 0.01, ***p< 
0.001, and ****p< 0.0001) (n= 3). UT ( un-treated sample), and T (treated sample). 
Figure 6: Differential mRNA expression profile of selected cytokines/chemokines 
produced by A549 cells challenged with pH1N1 and H3N2 pre-incubated with rfhSP-A 
(A&B) and FLSP-A (C&D). The expression levels of selected cytokines and chemokine were 
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measured using qRT-PCR and the data were normalized via 18S rRNA expression as a control. 
The relative expression (RQ) was calculated by using cells only time point as the calibrator. 
The RQ value was calculated using the formula: RQ = 2−ΔΔCt. Assays were conducted in 
triplicates and error bars represent ± SEM. Significance was determined using the unpaired 
one-way ANOVA test (**p< 0.01, ***p< 0.001, and ****p< 0.0001) (n=3). UT (untreated 
sample), and T (treated sample). 
Figure 7:  mRNA expression levels of pro-inflammatory cytokine, interferon (IFN) α in 
untreated and rfhSP-A (A) and FLSP-A (B) treated pH1N1 and H3N2 subtype of IAV. 
The expression levels of cytokines and chemokine were measured using qRT-PCR and the data 
were normalized via 18S rRNA expression as an endogenous control. The relative expression 
(RQ) was calculated by using cells only time point as the calibrator. The RQ value was 
calculated using the formula: RQ = 2−ΔΔCt. Assays were conducted in triplicates and error 
bars represents ± SEM. Significance was determined using the unpaired one-way ANOVA test 
(*p< 0.05, **p< 0.01, ***p< 0.001, and ****p< 0.0001) (n= 3 UT (untreated sample), and T 
(treated sample). 
Figure 8: Multiplex cytokine array analysis of supernatants collected at 24 h time point. 
A549 cells were challenged with (A) pH1N1 and (B) H3N2, following rfhSP-A (10 μg/ml) 
treatment. TNF-α, IL-6, IL-8, IL-12p40 and MCP-1 were measured using a commercially 
available MagPix Milliplex kit (EMD Millipore). Experiment was conducted in duplicates and 
error bars represent ± SEM (n= 3); significance was determined using unpaired one-way 
ANOVA test (*p< 0.05, **p< 0.01, ***p< 0.001 and ****p< 0.0001). UT (untreated sample), 































Figure 2   
24 
 
 
Figure 3 
 
25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 
26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 
27 
 
 
 
 
Figure 6A 
 
 
28 
 
 
 
 
 
 
 
 
Figure 6B 
29 
 
 
 
 
 
 
Figure 6C 
30 
 
 
 
 
 
 
 
Figure 6D 
31 
 
 
 
 
 
 
 
Figure 7 
32 
 
 
 
Figure 8A 
33 
 
Figure 8B 
 
 
 
